Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest medullary thyroid cancer Stories

2009-05-28 10:02:34

New guidelines designed to standardize and optimize the diagnosis, treatment, and monitoring of patients with Medullary Thyroid Carcinoma (MTC), an uncommon and challenging form of thyroid cancer, have been developed by the American Thyroid Association and published online ahead of print in Thyroid, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The guidelines are available free online at www.liebertpub.com/thy"Following careful peer review, Thyroid has...

2008-10-23 06:00:11

Exelixis, Inc. (Nasdaq:EXEL) today announced that GlaxoSmithKline (GSK) (LSE: GSK; NYSE: GSK) has decided not to exercise its option to license XL184. GSK also informed Exelixis that it had decided not to license the earlier compounds in the collaboration, including XL281, XL228, XL820, and XL844. As a result, Exelixis retains the rights to develop, commercialize, and/or license all of the compounds, subject to payment to GSK of a 3% royalty on net sales of any product incorporating XL184....

2008-08-29 03:00:19

By Zaydfudim, Victor Stover, Daniel G; Caro, Susan W; Phay, John E Although medullary thyroid cancer (MTC) can produce adrenocorticotropic hormone (ACTH) in up to 40 per cent of cases as determined by immunohistochemistry, clinical hypercortisolism is rarely seen. We report a medullary endocrine neoplasia 2A (MEN 2A) kindred whose proband case presented with Cushing's syndrome (CS). This 51-year-old woman presented with debilitating weakness, exertional dyspnea, 50 pound weight gain, moon...

2008-07-28 06:00:25

Exelixis, Inc. (Nasdaq:EXEL) today announced that it has notified GlaxoSmithKline (GSK) that it has achieved proof-of-concept for XL184 under the collaboration agreement between GSK and Exelixis, and has submitted the corresponding data report to GSK. Under the agreement, GSK has 90 days to review the data and decide whether to exercise its option to select the compound for further development and commercialization. If GSK selects XL184, Exelixis would receive a $55 million milestone...

2008-07-22 12:00:21

San Francisco-based biotech Exelixis has seen its shares rise after taking an investigational thyroid cancer drug into a Phase III trial. While the relatively low incidence of medullary thyroid cancer will limit the drug's commercial potential, the low barriers to market entry and high unmet need should help its chances of success, ultimately leading to a satisfactory return on development costs. The Phase III registrational trial is a randomized double-blind study evaluating XL184...

2008-07-21 12:01:26

Exelixis has initiated the Phase III registration trial of XL184 as a potential treatment for medullary thyroid cancer. The Phase III trial is a randomized, placebo-controlled, double-blinded study of XL184 as single-agent therapy in 315 patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Patients will be randomized in a 2:1 ratio to receive XL184 or placebo administered as a daily oral dose. The primary endpoint will be duration of...

2008-07-21 06:00:17

Exelixis, Inc. (Nasdaq:EXEL) announced today that the phase 3 registration trial of XL184 as a potential treatment for medullary thyroid cancer (MTC) has been initiated. XL184 is a small molecule anticancer compound targeting the MET, RET, and VEGFR2 receptor tyrosine kinases. Recently, Exelixis and the U.S. Food and Drug Administration (FDA) reached agreement on the phase 3 registration trial via the Special Protocol Assessment process. Exelixis has also discussed the trial design with...

2008-06-16 09:01:19

Exelixis and the FDA have reached agreement on the Phase III registration trial of XL184, a small molecule anticancer compound targeting MET, RET, and VEGFR2, via the special protocol assessment process. Exelixis has also discussed the trial design with European regulatory agencies. Exelixis is planning to initiate the Phase III trial of XL184 as a potential treatment for medullary thyroid cancer (MTC) this summer. The Phase III trial will be a randomized, placebo-controlled,...

2008-06-16 06:00:07

SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that the company and the U.S. Food and Drug Administration (FDA) have reached agreement on the phase 3 registration trial of XL184, a small molecule anticancer compound targeting MET, RET, and VEGFR2, via the Special Protocol Assessment process. Exelixis has also discussed the trial design with European regulatory agencies. Exelixis is planning to initiate the phase 3 trial of XL184 as a potential...